Mauna Kea Technologies (Paris:MKEA) (Euronext: MKEA, FR0010609263), leader in the optical biopsy market, announced today it has obtained a 510(k) regulatory clearance from the U.S. Food & Drug Administration (FDA) for Cellvizio in the field of urology. The clearance covers the use of, Cellvizio’s Uroflex™ B and CystoFlex™ F Confocal Miniprobes within anatomical tracts including but not limited to urethra, bladder, and ureter, accessed through an endoscope or endoscopic accessories.
Help employers find you! Check out all the jobs and post your resume.
